Diabetes giant Novo said to consider up to 3,000 layoffs as US pricing storms gather: report
“Uncertain and unpredictable markets” are forcing Novo Nordisk to consider dropping its longterm financial target and cutting 3,000 jobs from its global workforce, according to a local media report.
Borsen, a Danish business newspaper, cited anonymous sources in reporting that the giant diabetes drugmaker plans to unveil its cost-cutting package alongside second quarter results in August. According to the sources, the plan would include an adjustment of its growth forecast, which Novo put at 5% as recently as May.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
